Skip to main content
. 2018 May 18;9(38):25294–25303. doi: 10.18632/oncotarget.25334

Figure 2. Forest plots evaluating the prognostic role of CD68+ TAMs in bladder cancer patients.

Figure 2

(A) CD68+ TAMs with OS; (B) CD68+ TAMs with DSS; (C) CD68+ TAMs with PFS.